Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors

Laboratory Investigation

Volumn 75, Issue 3, 1996, Pages 413-426

  Zhang, Fang ^a   Riley, Joan ^a   Gant, Timothy W ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; GLYCOPROTEIN P; MESSENGER RNA; METHYLNITROSOUREA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOLOGIC TECHNIQUES; IN SITU HYBRIDIZATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE PROBES; P-GLYCOPROTEIN; RATS; RNA, MESSENGER; STAINING AND LABELING;

EID: 0029813834     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Bradley G, Sharma R, Rajalakshmi S, and Ling V (1992). P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52:5154-5161.
2. Brown PC, Thorgeirsson SS, and Silverman JA (1993). Cloning and regulation of the rat mdr2 gene. Nucl Acids Res 21:3885-3891.
3. Burt RK and Thorgeirsson SS (1988). Coinduction of MDR-1 multidrug resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 80:1381-1386.
4. Carr BI (1987). Pleiotropic drug resistance in hepatocytes induced by administration of carcinogens to rats. Cancer Res 47:5577-5583.
5. Cha RS, Thilly WG, and Zarbl H (1994). N-nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic H-ras1 gene mutations. Proc Natl Acad Sci USA 91:3749-3753.
6. Chaudhary PM and Roninson IB (1993). Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632-639.
7. Chin JE, Soffir R, Noonan KE, Choi K, and Roninson IB (1989). Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 9:3808-3820.
8. Chin K, Chauhan SS, Pastan I, and Gottesman MM (1990). Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Diff 1:361-365.
9. Chin K, Ueda K, Pastan I, and Gottesman MM (1992). Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
10. Choi K, Frommel THO, Stern RK, Perez CF, Kriegler M, Tsuruo T, and Roninson IB (1991). Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl. Acad. Sci. USA 88:7386-7390.
11. Chu BCF, Orgel LE (1985). Detection of specific DNA sequences with short biotin-labelled probes. DNA 4:327-331.
12. Cornwell MM, Tsuruo T, Gottesman MM, Pastan I (1987). ATP-binding properties of P-glycoprotein from multidrug resistant KB cells. FASEB J. 1:51-54.
13. Deuchars KL, Duthie M, Ling V (1992). Identification of distinct P-glycoprotein gene sequences in rat. Biochem. Biophys. Acta 1130:157-165.
14. Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers C, Farber E, and Cowan KH (1987a). Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 84:7701-7705.
15. Fairchild CR, Kao-Shan Chien-S, Wang-Peng J, Rosen N, Israel MA, Malera PW, Cowan KH, and Goldsmith ME (1987b). Isolation of amplified and overexpressed DNA sequences from adriamycin resistant human breast cancer cells. Cancer Res 47:5141-5148.
16. Frei E III (1985). Curative cancer chemotherapy. Cancer Res 45:6523-6537.
17. Futscher BW, Blake LL, Gerlach JH, Grogan TM, and Dalton WS (1993). Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 213:414-421.
18. Gant TW, Silverman JA, Bisgaard HC, Burt RK, Marino PA, and Thorgeirsson SS (1991). Regulation of 2-acetylaminofluorene-and 3-methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog 4:499-509.
19. Gasparini G, Bevilacqua P, Pozza F, Meli S, and Weidner N (1993). P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. Breast 2:27-32.
20. Goldie JH, Coldman AJ, and Gudauskas GA (1982). Rationale for the use of alternating non-cross-resistant chemotherapy: Cancer treatment reports. 66:439-449.
21. Gottesman MM and Pastan I (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
22. Hsu SI, Lothenstein L, and Horwitz SB (1989). Differential overexpression of three MDR gene family members in multidrug resistant J774.2 mouse cells. J Biol Chem 264:12053-12062.
23. Kato S, Nishimura J, Yufu Y, Ideguchi H, Umemura T, and Nawata H (1992). Modulation of expression of multidrug resistance gene (mdr-1) by adriamycin. FEBS Lett 308:175-178.
24. Kimanh-Thi N, Liu B, Ueda K, Gottesman MM, Pastan I, and Chin KV (1994). Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77.
25. Kohno K, Sato S, Takano H, Matsuo K, and Kuwano M (1989). The direct activation of human multidrug resistance gene by anticancer agents. Biochem Biophys Res Comm 164:1415-1421.
26. Kuo MT (1993). Expression of multidrug-resistance (P-glycoprotein) genes in liver cancers: A molecular example of the convergence theory of hepatocarcinogenesis. Mol Carcinog 7:73-75.
27. Linn SC, Giaccone G, VanDiest PJ, Blokhuis WMD, VanDer-Valk P, Van Kalken CK, Kuiper CM, Pinedo HM, and Baak JPA (1995). Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 6:679-685.
28. Lonn U, Lonn S, and Stenkvist B (1993). Reduced occurrence of mdr-1 amplification in stage IV breast cancer patients treated with tamoxifen compared with other endocrine treatments. Int J Cancer 53:574-578.
29. Nakatsukasa H, Silverman JA, Gant TW, Evarts RP, and Thorgeirsson SS (1993). Expression of multidrug resistance genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology 18:1202-1207.
30. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, and Ling V (1989). Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9:1224-1232.
31. O'Brien CA, Fan D, Ward N, Dong Z, Iwamoto L, Gupta KP, Earnest LE, and Fidler I (1991). Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. Biochem Pharmacol 41:797-806.
32. Ohkawa K, Hatano T, Isonishi S, Takada K, Joh K, and Matsuda M (1994). Doxorubicin enhances transient expression of P-glycoprotein and modulates activity and isoform expression of protein kinase C in AH66 rat hepatoma cells. Int J Oncol 4:655-659.
33. Pringle JH, Primrose L, Kind CN, Talbot IC, and Lauder I (1989). In situ hybridization demonstration of poly-adenylated RNA sequences in formalin-fixed paraffin sections using a biotinylated oligonucleotide poly d(T) probe. J Pathol 158: 279-286.
34. Pringle JH, Ruprai AK, Primrose L, Keyte J, Potter L, Close P, and Lauder I (1990). In situ hybridization of immunoglobulin light chain mRNA in paraffin sections using biotinylated or hapten-labelled oligonucleotide probes. J Pathol 162:197-207.
35. Raymond M, Rose E, Housman DE, and Gros P (1990). Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol 10:1642-1651.
36. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, and vanZwieten MJ (1990a). Comparative study of human and rat tumorigenesis. Lab Invest 63:244-278.
37. Russo J, Russo IH, Rogers AE, VanZwieten MJ, and Gusterson B (1990b). Tumours of the mammary gland. In: Turusov V, Mohr U, editors. Pathology of tumours in laboratory animals. Lyon: International Agency for Research on Cancer, 47-78.
38. Sanfilippo O, Ronchi E, DeMarco C, DiFronzo G, and Silvestrini R (1991). Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27:155-158.
39. Schinkel AH, Roelofs MEM, and Borst P (1991). Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific antibodies. Cancer Res 51: 2628-2635.
40. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, and Volm M (1989). P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60:815-818.
41. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, and Thorgeirsson SS (1993). Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 17:854-860.
42. Scotto KW, Biedler JL, and Melera PW (1986). Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232:751-755.
43. Shapiro AB and Ling V (1994). ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 269:3745-3754.
44. Shen D-W, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, and Gottesman MM (1986). Human multidrug-resistant cell lines: Increased mdr1 expression can precede gene amplification. Science 232:643-645.
45. Silverman JA and Hill BA (1995). Characterization of the basal and carcinogen regulatory elements of the rat mdr1b promoter. Mol Carcinog 13:50-59.
46. Silverman JA, Raunio H, Gant TW, and Thorgeirsson SS (1991). Cloning and characterization of the rat multidrug resistance (mdr) gene family. Gene 106:229-236.
47. Smit JJM, Schinkel AH, OudeElferink RPJ, Groen AK, Wagenaar E, VanDeemter L, Mol CAAM, Ottenhoff R, VanderLugt NMT, VanRoon MA, VanderValk MA, Offerhaus GJA, Berns AJM, and Borst P (1993). Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462.
48. Song R, Ikeguchi M, Zhou G, and Kuo MT (1995). Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. J Biol Chem 270:25468-25474.
49. Spandidos DA, Karaiossifidi H, Malliri A, Linardopoulos S, Vassilaros S, Tsikkinis A, and Field JK (1992). Expression of ras Rb1 and p53 proteins in human breast cancer. Anticancer Res 12:81-90.
50. Teeter LD, Becker FF, Chisari FV, Li D, and Kuo MT (1990). Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 10:5728-5735.
51. Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, and Kuo MT (1993). Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 8:67-73.
52. Thompson HJ and Adlakha H (1991). Dose-response induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res 51:3411-3415.
53. Thorgeirsson SS, Huber BE, Sorrell S, Fojo AT, Pastan I, and Gottesman MM (1987). Expression of the multidrug-resistance gene in hepatocarcinogenesis and regenerating rat liver. Science 236:1120-1122.
54. Ueda K, Cardarelli C, Gottesman MM, and Pastan I (1987). Expression of a full length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004-3008.
55. Urbatsch IL, AlShawi MK, and Senior AE (1994). Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 33:7069-7076.
56. Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozolls RF, Hamilton TC, Joenje H, and Borst P (1988). Genes amplified and overexpressed in human multidrug resistant cell lines. Cancer Res 48:5927-5932.
57. Van der Bliek A, Van der Velde-Koerts T, Ling V, and Borst P (1986). Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol 6:1671-1678.
58. Verrelle P, Meisonnier F, and Fonck Y (1991). Clinical relevance of immunhistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111-116.
59. Vollrath V, Wielandt AM, Acuna C, Duarte I, Andrade L, and Chianale J (1994). Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol 21:754-763.
60. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, and Coon JS (1991). Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726.
61. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuro T, and Kaye SB (1990). P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 62:758-761.
62. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, and Barbacid M (1985). Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315:382-385.
63. Zastawny R, Salvino R, Chen J, Benchimol S, and Ling V (1993). The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8:1529-1535.
64. Zhang F, Riley J, and Gant TW (1996). Use of internally controlled RT-PCR for absolute quantitation of individual multidrug resistant gene transcripts in tissue samples. Electrophoresis 17:255-260.